Nuvectis Pharma gets FDA clearance to begin Phase 1 trial for NXP900

Nuvectis Pharma, Inc.

FDA cleared IND for NXP900, including Phase 1 clinical trial protocol.
NXP900 is a precision oncology drug; Nuvectis now has two clinical-stage candidates.
CEO Ron Bentsur: IND clearance is a significant milestone for corporate strategy.
NXP900 targets cancers with unmet medical need via differentiated mechanism of action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.